Kennedy Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	+352,302	New	+$9.6M	0.24%	157
2024 Q2	–	Sell	-33,586	Closed	-$1.41M	–	710
2024 Q1	$1.41M	Sell	33,586 -28,586	-46%	-$1.17M	0.03%	581
2023 Q4	$2.47M	Sell	62,172 -25,222	-29%	-$742K	0.05%	451
2023 Q3	$2.41M	Buy	87,394 +166	+0.2%	+$5.2K	0.06%	421
2023 Q2	$2.96M	Buy	87,228 +5,862	+7%	+$198K	0.07%	396
2023 Q1	$2.93M	Buy	81,366 +47	+0.1%	+$2.03K	0.09%	352
2022 Q4	$3.62M	Sell	81,319 -31	-0%	-$1.11K	0.1%	334
2022 Q3	$2.29M	Buy	81,350 +57,034	+235%	+$1.75M	0.07%	395
2022 Q2	$656K	Sell	24,316 -201	-0.8%	-$5.84K	0.02%	519
2022 Q1	$835K	Sell	24,517 -3,641	-13%	-$116K	0.02%	517
2021 Q4	$1.09M	Buy	+28,158	New	+$1.23M	0.02%	506